60 Degrees Pharmaceuticals (SXTP) Competitors $1.75 -0.41 (-18.98%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.74 -0.01 (-0.86%) As of 07/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SXTP vs. NEUP, FLGC, PMN, AIMD, ME, IMCC, ALVR, LPTX, NXTC, and TRIBShould you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Neuphoria Therapeutics (NEUP), Flora Growth (FLGC), Promis Neurosciences (PMN), Ainos (AIMD), 23andMe (ME), IM Cannabis (IMCC), AlloVir (ALVR), Leap Therapeutics (LPTX), NextCure (NXTC), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. 60 Degrees Pharmaceuticals vs. Its Competitors Neuphoria Therapeutics Flora Growth Promis Neurosciences Ainos 23andMe IM Cannabis AlloVir Leap Therapeutics NextCure Trinity Biotech 60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Does the media favor SXTP or NEUP? In the previous week, 60 Degrees Pharmaceuticals had 6 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 7 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.87 beat 60 Degrees Pharmaceuticals' score of 0.62 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 60 Degrees Pharmaceuticals Positive Neuphoria Therapeutics Very Positive Do analysts rate SXTP or NEUP? 60 Degrees Pharmaceuticals presently has a consensus target price of $7.00, suggesting a potential upside of 300.00%. Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 177.78%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Neuphoria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SXTP or NEUP more profitable? Neuphoria Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -1,947.30%. Company Net Margins Return on Equity Return on Assets 60 Degrees Pharmaceuticals-1,947.30% N/A -174.90% Neuphoria Therapeutics N/A N/A N/A Do insiders and institutionals have more ownership in SXTP or NEUP? 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, SXTP or NEUP? 60 Degrees Pharmaceuticals has higher revenue and earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio60 Degrees Pharmaceuticals$300K8.58-$7.95M-$50.41-0.03Neuphoria Therapeutics$10K1,421.28-$15.49MN/AN/A Which has more risk and volatility, SXTP or NEUP? 60 Degrees Pharmaceuticals has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Summary60 Degrees Pharmaceuticals and Neuphoria Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTP vs. The Competition Export to ExcelMetric60 Degrees PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.19M$2.44B$5.62B$9.30BDividend YieldN/A1.79%4.25%4.03%P/E Ratio-0.039.1428.5719.58Price / Sales8.58676.39423.3093.84Price / CashN/A164.3436.0257.93Price / Book-0.274.608.135.54Net Income-$7.95M$30.99M$3.24B$257.73M7 Day Performance-28.86%-1.81%0.16%-0.08%1 Month Performance-18.98%5.73%5.95%8.09%1 Year Performance49.57%-7.03%26.09%13.02% 60 Degrees Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTP60 Degrees Pharmaceuticals2.815 of 5 stars$1.75-19.0%$7.00+300.0%+52.4%$3.19M$300K-0.033News CoverageAnalyst ForecastGap DownHigh Trading VolumeNEUPNeuphoria Therapeutics2.2209 of 5 stars$7.30+2.0%$21.00+187.7%N/A$13.72M$10K0.00N/AFLGCFlora Growth2.6224 of 5 stars$0.60+3.4%$4.00+562.3%-39.9%$13.63M$59.51M-0.62280Positive NewsPMNPromis Neurosciences3.0886 of 5 stars$0.41+0.3%$4.50+997.6%-79.3%$13.40MN/A-8.205News CoverageAnalyst ForecastGap DownAIMDAinos1.5593 of 5 stars$3.19-3.3%N/A-28.4%$13.37M$20K-0.4940ME23andMeN/A$0.50-35.3%N/A-94.9%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeIMCCIM Cannabis0.1599 of 5 stars$3.30flatN/A+11.9%$13.33M$39.44M-5.16340ALVRAlloVirN/A$2.61+4.4%N/A-85.6%$13.16MN/A-0.13110LPTXLeap Therapeutics2.2261 of 5 stars$0.31+10.3%$3.38+978.3%-84.6%$12.97MN/A-0.1840Positive NewsGap DownNXTCNextCure4.3506 of 5 stars$0.46+4.5%$3.50+659.2%+185.0%$12.93MN/A-0.2690Analyst ForecastTRIBTrinity Biotech1.1541 of 5 stars$0.71-3.5%N/A-76.9%$12.80M$61.56M-0.25480Positive News Related Companies and Tools Related Companies NEUP Competitors FLGC Competitors PMN Competitors AIMD Competitors ME Competitors IMCC Competitors ALVR Competitors LPTX Competitors NXTC Competitors TRIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTP) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTP Stock Alerts